Index

A
Abbey, K., 27
Abbreviated/portable recordings
audio/taping/video/taping, 188
daytime nap, 191–192
home multichannel monitoring, 190–191
oximetry, 188–190
Absolute pulse rate increase (APRI), 189, 190
Achondroplasia
central hypoventilation syndromes, 399
with craniofacial syndromes, 341
Acid maltase deficiency (AMD), 315
Acquired central hypoventilation syndromes, 400–401
Actigraphy, 177
adolescents, 177, 179, 182
ambulatory assessment, 178
clinical applications, 181
clinical considerations
artifacts, 182
care and return of device, 184
current procedural terminology (CPT) code, 184
indications, 181
periodic limb movement disorder, 180, 181
placement of device, 182
prolonged night wakings, 181, 182
prolonged sleep onset latency/restless sleep, 181, 183
recording time, 182
reimbursement, 184
pediatric sleep medicine, validity of agreement, 178–180
Bland–Altman concordance technique, 178–180
correlation of total sleep time (TST), polysomnography, 179, 180
recommendation, 178
sensitivity and specificity, 179
statistical techniques, 178
videosomnography, 179
sleep-disordered breathing, 178
toddlers, 177, 182
validation, 181, 182, 184
Adams, J.A., 266
Adams, R.J., 330
Adenoidectomy, 511
Adenoids, 222–223, 522, 524, 525
facies, 168
and tonsillar enlargement, lateral neck X-ray, 165
Adenosine, 67
Adenotonsillar hyperplasia, 510
Adenotonsillar hypertrophy, 26, 32, 165, 280, 341
transcriptomics, 239
Adenotonsillectomy (AT), 532
indications
recurrent infection, 510
sleep-disordered breathing, 510–511
OSA, 509
Down syndrome, 307
health-care utilization reduction, 413–414
pediatric, 515–517
standard therapy, 280
surgical complications
delayed postoperative complications, 513
electrocautery, 513
hemorrhage, 512
impact of SDB, 514–515
intracapsular tonsillectomy, 514
intraoperative/immediate postoperative complications, 512–513
long-term complications, 513–514
risk factors, 515
surgical principles
adenoidectomy, 511
lingual tonsillectomy, 511
tonsillectomy, 511
ADHD. See Attention deficit hyperactivity disorder (ADHD)
Adiponectin, 296
Adolescents, cyclic alternating pattern, 79
Adults, autonomic cardiovascular regulation during sleep
effects of, 92–94
maturation, 91–92
African–American race, 386
Airflow assessment, in polysomnography, 202, 203
nasal, 47–48
Airway inflammation, 522
Airway occlusion, arousal in infants, 108
Alexopoulos, E.I., 526
Al-Ghamdi, S.A., 526
Ali, N.J., 283, 286, 444, 446
Aljadeff, G., 478
Allen, M.B., 375
Allergic rhinitis, 386
and sleep disturbances, 51–52
Altman, D.G., 189
American Academy of Pediatrics (AAP), 509, 532
American Academy of Sleep Medicine, 178
Amin, R., 366, 368
Amin, R.S., 479, 480
Anders, T.F., 74
Andreou, G., 305
Animal models, neuromuscular disorders, 316
Anti-inflammatory agents, 526
combinatorial approaches, 526–527
Anuntaseree, W., 283
Aortic body (AB), 135
Apert syndrome, 338
Apnea, 19, 204
termination, chemoreceptor, 141, 142
Apnea–hypopnea index (AHI), 188, 189, 247–248,
250, 516, 517
Apnea of prematurity (AOP)
bradycardia-desaturation relationship, 264–266
changes in lung volume and desaturation, 266–267
chest wall distortion, anatomic dead space, and
diaphragmatic fatigue, 268–269
feeding and gastroesophageal reflux, role of, 267–268
gastroesophageal reflux (GER), 419
hypoxic ventilatory depression, 269–270
pCO2 threshold, 270
termination, 270–271
thermal environment, 270
treatment
caffeine, 272–273
continuous positive airway pressure, 272
doxapram, 274–275
incremental treatment plan, 271
nasogastric feeding tube placement, 273
olfactory stimulation, 274
oscillating waterbed, 273–274
oxygen administration, 274
prone head-elevated positioning, 271–272
red blood cell transfusions, 274
synchronized nasal ventilation, 272
upper airway obstruction, role of, 264
Apparent life-threatening events (ALTEs), 419
Archbold, K.H., 447
Arcuate nucleus, 125
Arens, R., 5, 7, 220, 222–224, 226, 386, 397
Argamaso, R.V., 344
Arman, A.R., 455
Arousal, 141, 142, 156–157
children, 109–111, 115, 116
definitions and methodology
cyclic alternating pattern (CAP), 110–111
electrocortical arousals, 109–110, 112
peripheral arterial tonometer (PAT), 112, 113
pulse transit time (PTT), 112–113
sleep pressure score (SPS), 113–115
effects and ventilatory control instability, 19
functional anatomy of, 106–107
in obstructive sleep-disordered breathing, 115–116
ontological perspective, 107–108
physiology of, 107
REM and NREM, 107, 109
responses from sleep, chemoreceptors role, 139–140
scoring, 200
SDB
cyclic alternating pattern scoring, 252
DAP events, 252
intra-class correlation coefficient, 251
markers, 251
spontaneous, 105
subcortical, 105, 109
sudden infant death syndrome (SIDS), 108–109
sympathetic activation measures, obstructive
apneas, 107, 113
threshold, 115
Aserinsky, E., 195
Asthma and obstructive sleep apnea
epidemiological overlap, 386–388
united airway concept, 385–386
AT. See Adenotonsillectomy (AT)
Atherogenesis, 481–482
Atlantoaxial subluxation, 514
Atonia, 66
Atrostim phrenic nerve stimulation
(PNS) device, 558
Attention deficit hyperactivity disorder (ADHD)
DSM-IV-TR category, 429
and sleep
clinical and community-based settings, 429
neuroanatomic structures, 429
polysomnography (PSG), 430
socioeconomic status, 429
Audiotaping recordings, 188
Autonomic cardiovascular regulation, during sleep
assessment of
baroreflex sensitivity, 88
blood pressure, 88
heart rate, 86–88
peripheral arterial tonometry, 88–89
pulse transit time (PTT), 89
clinical implications, 98
effects of
adults, 92–94
children, 94–97
infants, 96–98
physiological parameters, 92
maturation
adults, 91–92
Index

children, 91
infants, 89–91
non-rapid eye movement (NREM), 92, 93
polysomnography, 95
quiet sleep (QS), 90, 92, 96
rapid eye movement (REM), 92, 93
Autonomic dysregulation, 305
Autonomic nervous system (ANS), 85–86, 478–479
Avery breathing pacemaker system, 558, 559, 572
Avery, R.E., 555
Autonomic dysregulation, 305
Autonomic nervous system (ANS), 85–86, 478–479
Avery breathing pacemaker system, 558, 559, 572
Avery, R.E., 555

B
Baharav, A., 94, 95
Ballard, R.D., 369
Baroreflex sensitivity, autonomic function assessment, 88, 90, 91, 93, 98
Basal cells, 41–42
Basal forebrain, sleep and circadian rhythms, 67–68
Basha, S., 503
Basic rest-activity cycle (BRAC), 60, 61
Baumert, M., 251
B cell fates, 30
Beard, G.M., 554
Beckenham, E.J., 171
Becker, D.A., 355
Bedwetting. See Nocturnal enuresis
Beebe, D.W., 453
Behavioral disorders, SDB
attention deficit hyperactivity disorder (ADHD), 429–430
case study, 435–436
cause and effect, 433
clinical approaches, 435–437
insufficient sleep, daytime sleepiness, and performance decrements, 434
potentially mechanisms, 433–434
sleepiness, 432–433
treatment, 436–437
Bell, E.F., 274
Beran, R.G., 357
Berger, H., 74
Bernkopf, E., 545
Bhattacharjee, R., 482, 483, 516, 517
Blushan, B., 497
Bidad, K., 283
Bi-level positive airway pressure (BPAP), 533, 534, 536, 537
ventilation, 402
Bixler, E.O., 52, 283, 286
Bland–Altman concordance technique, actigraphy, 178–180
Bland, J.M., 189
Blood pressure, autonomic function assessment, 86, 88, 90, 91, 93, 97
Blood pressure variability (BPV), 88
Blunden, S., 444, 447, 450, 452
Bojsen-Moller, F., 42
Borbely, A.A., 77
Bower, C.M., 431
Bradley, S., 367
Brady, P., 42
Braiding, P., 42
Brady, S., 367
Bradyarrhythmia, 264–266
Brain-behavior equation, 456–458
Brain regulatory mechanisms
cerebellar injury, 470
Cheyne-Stokes breathing, 470
congenital central hypoventilation syndrome (CCHS)
cerebellar injury, 470
chemosensitivity, 463–464
CO₂ sensitivity, loss of, 462–463
hypothalamic injury, 465–466
loss of perception, 466–467
neurotransmitter structures, 465
O₂ functional differences, 463
O₂ sensitivity, loss of, 463
phox2b expression, 462
processes enhancing ventilation, 468
state-related hypoventilation, 467
thermoregulatory drive, 465
hypoxia, 464–465
motion-induced influences, 470
obstructive sleep apnea (OSA)
cerebellar injury, 468–469
functional cerebellar impairments, 469
upper airway muscle activity and diaphragmatic patterning, 468
state dependency, respiratory patterning, 470–471
Brainstem nuclei
breathing and, 140–141
central chemoreception and breathing generation, 140
sleep and circadian rhythms, 63–65
Breathing
and chemoreceptors, during sleep
in arousal responses, 139–140
brain/brainstem nuclei, 140–141
central chemoreception, brainstem nuclei, 140
effect on breathing control, 138–139
phases of, 137, 138
Brietzke, S.E., 515, 516
Brodsky, L., 223
Brouillette, R.T., 52, 172, 189, 253, 526
Brown, J.K., 359
Brunetti, L., 284, 286, 455
Bruni, O., 350
Budesonide, 526
Burstein, F.D., 308
Burszttein, C., 350
Bush, P.G., 339

[577]
Caffeine, 272–273
Calhoun, S.L., 451, 453
Campbell, I.G., 76
CAP. See Cyclic alternating pattern (CAP)
Capnometry, 202
Cardiac remodeling, 480–481
Cardiovascular dysfunction
adverse ramifications, 475
obstructive sleep apnea (OSA)
adult studies, 475–476
autonomic dysfunction, 478–479
endothelial dysfunction, 482–484
impact of obesity, 476–478
systemic hypertension, 479–480
systemic inflammation and atherosclerosis, 481–482
ventricular remodeling, 480–481
Carotid bodies (CB), 135–136, 142–144
Carroll, J.L., 294
Carskadon, M.A., 305
Carvalho, L.B.C., 450, 453
Cash, S.S., 75
Castronovo, V., 283, 285, 286
Catecholaminergic neurons, 141
CCHS. See Congenital central hypoventilation syndrome (CCHS)
CD4+ and CD8+, in tonsillar tissues, 32
Central chemoreception and breathing generation, brainstem nuclei, 140
Central hypoventilation syndromes
achondroplasia, 399
acquired, 400–401
Chiari malformation (CM)
clinical management, 396–397
clinical presentation, 396
type I and II, 396
chronic respiratory failure
chemoreceptors, 392
components, 392
ventilatory control, 392
chronic ventilatory support
modalities of, 402–403
philosophy of, 401–402
congenital (see Congenital central hypoventilation syndrome (CCHS)) Joubert syndrome, 400
Leigh syndrome, 399–400
obesity, 398
Prader–Willi syndrome (PWS)
clinical management, 397–398
respiratory control abnormalities, 397
rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD), 398–399
respiratory control disorders, 401
Central pattern generator (CPG), 137–138
Cephalometry, 220, 223
of upper airway, 5, 8, 170
Cerebellar Purkinje neurons, 469
Chemoreceptors
breathing, phases of, 137, 138
carotid bodies (CB), 135–136
CO2, chemoreceptor sites, 136, 137
congenital central hypoventilation syndrome, 145
myelomeningocele (myelodysplasia), 145–146
neonatal sleep-related breathing disorders, 146
and normal breathing, during sleep
apnea threshold, 139
in arousal responses, 139–140
brain/brainstem nuclei, 140–141
central chemoreception, brainstem nuclei, 140
effect on breathing control, 138–139
hypoxic ventilatory response, 139
O2 and CO2
aortic body (AB), 135
central, 135
chemosensitivity, concept of, 134–135
dynamic delivery system, components, 134
overlap and interaction, 137
oxidative metabolism, 134
peripheral, 135
principles, 134
respiratory control system, 134
sites of, 135
peripheral, 138, 139, 146
postnatal development and plasticity, 138
Prader–Willi syndrome, 146
respiratory central pattern generator (CPG), 137–138
in sleep-disordered breathing
chronic intermittent hypoxia, peripheral chemoreceptors, 142–145
obstructive sleep apnea, peripheral chemoreceptors, 141–142
tobacco smoke exposure and sleep, 147
Chemosensitivity, CCHS, 463–464
Cheyne-Stokes breathing, 470
Chiari malformation (CM), 145, 146
clinical management, 396–397
clinical presentation, 396
type I and II, 396
Child-friendly sleep laboratory, polysomnography, 198
Children
autonomic cardiovascular regulation, during sleep
effects of, 94–97
maturation, 91
lymphadenoid tissues, immunological characteristics
lymphocyte migration, in palatine tonsils, 31
palatine tonsils, immunological response in, 30–31
nose and sleep-disordered breathing, 52–53
OSA, lymphadenoid tissues, 31–33
Chng, S.Y., 52, 284, 387
Chronic intermittent hypoxia (CIH), 133
peripheral chemoreceptors role, 142–145
Circadian rhythm, 60. See also Sleep and circadian rhythms, neural mechanisms and metabolism, 122, 127–128
CO₂ chemoreceptor, 134–137
Cognition, nonacquired knowledge, 446–451
cyclic alternating pattern (CAP), 453
dimensions, 444
ear-nose-throat (ENT) clinics, 444
“g-effect,” 454
high-sensitivity C-reactive protein (hsCRP) levels, 452
impact of SDB, 444–445
memory problems, 454
mild deficits, 444
moderating effect, 453
sensorimotor function and perceptual ability, 452
Stroop effect, 453
Cohen, S.R., 344
Computational fluid dynamics (CFD), 219
Computed tomography (CT), 218
upper airway evaluation, 171
Conduct disorder (CD), 431–432
Congenital central hypoventilation syndrome (CCHS)
cerebellar injury, 470
chemoreceptors in, 145
chemosensitivity, 463–464
clinical presentation, 393–394
CO₂ sensitivity, loss of, 462–463
diagnostic evaluation and clinical management abnormalities and PHOX2B gene mutation, 394 follow-up care, 396 progressive pulmonary hypertension, 395 ventilatory responses, 394 diaphragm pacing (see Diaphragm pacing, congenital central hypoventilation syndrome) epidemiology, 393 hypothalamic injury, 465–466 loss of perception, 466–467 neurotransmitter structures, 465 O₂ functional differences, 463 O₂ sensitivity, loss of, 463 outcome, 396 PHOX2B gene, 393 processes enhancing ventilation, 468 state-related hypoventilation, 467 thermoregulatory drive, 465
Connors, C., 429
Connexin 36, 65
Continuous positive airway pressure (CPAP), 496 adenotonsillectomy, 532 adherence, 533–535 adverse effects, 535–536 aerophagia, 535 apnea of prematurity (AOP), 272 claustraphobia, 535, 536 Down syndrome, 307–308 efficacy of, 533 equipment issues, 536 follow-up visits, 539 indications, 532 institution and behavioral modification programs, 536–538 interface, 536 neurobehavioral effects, 533 pediatric, 532, 534, 536 psychosocial effects, 533 side effects, causes and management, 535 treatment of, in adults, 476 Croft, C.B., 171
Crouzon syndrome, 338
Cyclic alternating pattern (CAP), 453, 549, 550 in adolescents, 79 arousal, 110–111 during development, course of, 79, 80 EEG frequency components, ontogeny of, 80 in newborns and infants, 78 non-CAP (NCAP), 77 parameters, 77, 79 in peripubertal children, 79 in preschool children, 78 in school-age children, 78–79
Cysteinyi leukotrienes, 523, 525
Cystic fibrosis (CF) consequences in metabolic, immune, and inflammatory responses, 374–375 pulmonary hypertension and cor pulmonale, 373 symptoms, quality of life, and neurocognition performance, 373–374
Cystic fibrosis (CF) (Cont.)
- noninvasive ventilation, 377–378
- oxygen therapy, 376–377
- sleep and gas exchange, acute exacerbations, 375
- sleep-disordered breathing
  - nocturnal hypventilation, 368–370
  - nocturnal hypoxemia and sleep disruption, 370–371
  - obstructive sleep apnea syndrome, 370
- sleep loss
  - bronchodilators, 372
  - gastrointestinal disorders, 372
  - links, 371–372
- sleep quality
  - actigraphy, 367–368
  - architecture, 366–367
  - night-to-night variation, 367
  - questionnaire, 366
- upper airway abnormalities, 378

D
- Dahlqvist, A., 304
- Dancey, D.R., 367
- Daytime sleepiness, 166
- de Beer, N.A., 88
- de Castro-Silva, C., 366–368, 378
- Delasnerie-Laupretre, N., 284
- de Miguel-Díez, J., 303
- de Moura, C.P., 308
- Denny, A., 345
- Dental malocclusion, 168
- Dentofacial abnormalities, 168
- Derkay, D.S., 510
- Desager, K.N., 387
- Desaturation, 264–267
- Desmopressin, 503
- Detrusor-dependent enuresis, 501
- Developmental neuropsychology
  - achievement tests, 443
  - acquired knowledge, 454–456
  - brain and behavior interrelation, 442
  - brain-behavior equation, 456–457
  - brain disruptions, 443
  - genetic code, 443
  - immature evaluation, 443
  - nonacquired knowledge, 444–454
- Devinsky, O., 357
- Diaphragmatic action potential amplitude (DAPA), 566
- Diaphragm pacing, congenital central hypoventilation syndrome, 403
  - artificial ventilatory support, electrical stimulation, 554
- Atrostim phrenic nerve stimulation (PNS), 558
- Avery Model S-242, 555
- Avery system, 558, 559
- candidate selection, 559–561
  - mechanical ventilation, 560
  - obese patients, 560
- PHOX2B mutation, 560
- phrenic nerve, integrity, 559
- polyalanine repeat expansion mutations, 560
- tracheal decannulation, 561
- considerations for, 567–568
- ECG channel, 569
- history of, 554–556
- implantation techniques, 561–564
  - chronological development and anatomical location, 561
  - direct stimulation, 562
  - lung ventilation, 562
  - neck implantation, 561
  - patient positioning, 562
  - receivers, 563
  - SILASTIC\textsuperscript{\textregistered} pouch, 563, 564
  - thoracoscopic implantation, 562
  - thoracoscopic view, of phrenic nerve, 563, 564
- thoracotomies, 561
- implanted phrenic nerve electrodes, 559
- loss of automatic breathing, 554
- Mark IV transmitter, 556, 558
- medical management, 565–567
  - initiation, 567
  - inspiratory time, 565, 566
  - pacer settings, determination of, 565–567
  - timing, 565
- NeuRx Diaphragm Pacing System, 558
- oscilloscope image, failed electrode/damaged phrenic nerve, 570
- outcomes
  - infection, 571
  - long-term management, information, 572
  - mechanical injury, to phrenic nerve, 571
  - receiver failure and electrode wire/insulation breakage, 571
- phrenic nerve electrode wire and receiver, 558
- platinum electrode, 559, 563, 564
- radio-frequency (RF) signal, 566, 570
- rationale for
  - facilitating speech, 557
  - negative pressure ventilation, 557
  - portability, 556–557
  - tracheostomy decannulation, 557
- technology, 557–559
- troubleshooting pacer malfunction, 568, 570–571
- twiddler’s syndrome, 560, 571
- Dillon, J., 430
- Diuresis-dependent enuresis, 501
- Dobbin, C.J., 367, 375
- Don, G.W., 224
- Donnelly, L.F., 304
- Douglas, B., 344
- Douglas, N.J., 223
- Down syndrome, 5, 15, 224
  - consequences of, 305
  - diagnosis, 306
  - differential diagnosis, 305–306
  - epidemiology, 303–304
  - OSAS with craniofacial anomalies, 340–341
Index

pathophysiology
autonomic nervous system dysregulation, 305
hypoplasia, 304
hypothyroidism, 305
hypotonia, 304
polysomnography, 201
treatment
adenotonsillectomy, 307
allergic rhinitis and noxious agents, 306
continuous positive airway pressure, 307
occipitoatlantal instability, 307
rapid maxillary expansion (RME), 308
tracheostomy placement, 308
Dubern, B., 483
Duchenne, G.B.A., 555
Duchenne muscular dystrophy (DMD), 314
Dyken, M.E., 304, 305
Dynamic respiration-gated techniques, 218

E
Eagle syndrome, 513
Ear nose throat (ENT) clinic, 455
EdenTec® monitor, 190
EDS. See Excessive daytime sleepiness (EDS)
Electrocardiogram (ECG), 205
channel, diaphragm pacing impulses, 569
Electro cortical (EEG) arousals, 112
arousal index, 109
definition, 109
intraclass correlation coefficient (ICC), 110
respiratory cycle-related EEG changes (RCREC), 110
Electroencephalogram (EEG), 62, 63, 81
electrode placement, International 10-20 system, 199, 200
and sleep during development
age-related topographic changes, 77
cyclic alternating pattern (CAP), 77–80
K complexes, 75–76
sigma band, 74
slow-wave activity (SWA), 76–77
spindle activity, 74–75
tracé alternant, 74, 77
Electromyogram (EMG)
chin, 199
limb, 205
Electrooculogram (EOG), 199, 201
Ellington, R.J., 74
Ellwood, E.T., 399
Endoscopic evaluation, upper airway, 171
End-tidal CO₂ (ETCO₂), 202
Enuresis alarm, 503
Epidemiology, pediatric OSA. See Pediatric obstructive sleep apnea (OSA), epidemiology
Epiglottis, 9, 10
Epilepsy
clinical features
Angel man syndrome, 355
higher BMI, 355
Rett syndrome, 356

diagnostic tools
intervention strategies, 356–357
polysomnography, 356
Sleep Apnea scale-Sleep Disorders Questionnaire (SA-SDQ), 356
epidemiology and prevalence, 354–355
mechanisms
SDB-related hypoxia, 358
SDB-related sleep deprivation, 358
SDB-related sleep fragmentation, 357
sleep disruption, 358
therapies, 360
respiratory control
central sleep apnea, 359–360
sudden unexpected death in epilepsy (SUDEP), 360
Epithelium, nasal, 41–42
Erickson, B.K., 510, 511
Ersu, R., 283, 387
Esophageal pressure (Pes), 200
Ethmoid sinuses, 40
Eustachian tube, 511
Event-related potential (ERP), 456
Excessive daytime sleepiness (EDS)
in clinical sample
frequency in groups, 294–295
subjective and objective measures, 294
in general population sample
anxiety/depression, 294
waist circumference, 293–294
wheezing/nocturnal asthma, 294
Extremely low gestational age neonate (ELGAN), 269

F
Facial dysmorphism, 168–169
Fallone, G., 434
Fatty acid-binding protein gene 4 (FABP4), 497
Feeding and sleep, 124–125
Feinberg, I., 74, 76, 80
Fenner, A., 268
Ferreira, A.M., 284, 455
Ferri, R., 80
Finapres™, 88
Finley, J.P., 91
Finometer™, 88
FitzGerald, G.A., 306
Flemming, W., 30
Fluoroscopy, upper airway evaluation, 170
Fluid-solid interaction (FSI) models, 219
Fluticasone, 526
Foldvary-Schaefer, N., 359
Follicles, 26, 29
Follicular dendritic cells (FDC), 29
Follicular germinal center, 30
Food and Drug Administration (FDA), diaphragm pacer system, 555, 557, 558
Foo, J.Y., 189
Fragmented sleep and neurophysiological disruption, 434–435
Franceschetti, 340
Frangolias, D.D., 371
Fregosi, R.F., 8, 220
Fricke, B.L., 305
Friedman, B.C., 448, 452
Friedman, M., 168, 516
Friedman palate position (FPP), 168
Friedman staging system (FSS), 168
Frontal sinuses, 40
Fujioka, M., 219
Functional residual capacity (FRC), 266–267

G
GABAergic neurons, 140
Gallaghe, D., 515, 516
Gas exchange, sleep study and MSLT, 202–204
Gastroesophageal reflux (GER)
apnea of prematurity (AOP), 419
apparent life-threatening events (ALTEs), 419
laryngopharyngeal reflux
endoscopically diagnosis, 421–422
hypopharyngeal sensor, 423
obstructive-reflux events relationship, 421–422
schematic representation, 421
symptoms, 420
mechanisms of, 418
and obstructive sleep apnea (OSA), 420
protective airway reflexes, 418
sleep-associated factors, 418
Genioglossus (GG) muscle, 16, 17
Genome-wide association study (GWAS), 237
Genomics, 236–237
of sleep disorders, 237–238
Germinal center (GC), 30
Ghrelin, 125, 127
Gibbs, A., 75
Gibbs, E.L., 75
Gil, E., 251
Giordani, B.J., 435, 453
Gislason, T., 284, 286
Glenn, W.W., 555
Glomus cells, 136
Glossoptosis, 304
Glucocorticoid receptors (GCR), 525
Glucose homeostasis and sleep, 124, 126
Goblet cells, 42
Goder, R., 353
Goldbart, A.D., 523, 524, 526
Goldenhar, M., 340
Goldenhar syndrome, 340
Goldstein, N.A., 188, 307
Gonadal axis and sleep, 123–124
Gonadotropins, 124
Goodwin, J.L., 283
Gorlin, R.J., 340
Goto, M., 91
Gozal, D., 170, 241, 253, 293, 294, 367, 433, 435, 452, 481–483
Graf, K.L., 420
Green, R.P., 510
Grisel’s syndrome, 514
Growth hormone, 61
axis and sleep, 122
Guilleminault, C., 223, 516, 532
Guimaraes, C.V., 304

H
Habitual snoring (HS), 155, 165, 502–503
definition, 246
OSA
morbidity, 282, 285
prevalence and risk factors, 282–284
Haponik, E.F., 14
Harvey, J.M.M., 446
Headaches
clinical features
cluster headache, 351
obesity, 350
tension-type, 351
diagnostic tools
actigraphy, 352
Children’s Sleep Habits Questionnaire
(CSHQ), 351
intervention strategies, 352–353
polysomnography (PSG), 352
sleep logs, 351
epidemiology and prevalence, 349–350
pathophysiology
screening tools and PSG, 354
SDB-induced hypothalamic dysregulation,
353–354
SDB-induced hypoxia and hypercapnia, 353
Health-care utilization
adenotonsillectomy, 413–414
categories, 411
cost, 411–412
medical records, 412–413
methods, 410
morbidity, 412
rate of referral, 412
Heart rate, autonomic function assessment, 89, 90, 93
children, 91
high-frequency (HF)/low frequency (LF), 87
infants, 89, 90
spectral bands, 87–88
time domain methods, 87
Heart rate variability (HRV), 86–88
Heng, K., 350
High-altitude pulmonary edema, 305
High enthothelial venules (HEV), 28
High-sensitivity C-reactive protein (hsCRP), 452, 522, 523
Hobson, J.A., 441
Hodges, E.K., 433
Hogan, E., 330
Hollinger, P., 357
Home audiotape recording, 188
Home mechanical ventilation, 397, 402
Index

Home multichannel monitoring
cardiorespiratory and videotape recording, 191
POLY-MESAM (P-M), 190, 191
SnoreSat and EdenTec monitor, 190
Home video recording, 188
Honer, R.L., 8
Hormonal regulation, during sleep. See Metabolic and hormonal regulation, during sleep
Horne, R.S.C., 95, 479
Huang, J., 115
Hufeland, C.W., 554
Hunt, C.E., 555
Hypercapnia, 140
Hypercarbia, 304
Hypernasality (rhinolalia aperta), 513
Hypnogram, 207
Hypocretin/orexin, in sleep-wake and metabolic regulation, 126–127
Hypofrontality, 68, 69
Hypopharynx, 6–7, 214
Hypoplasia, 304
Hypopnea, 204
Hypothalamic orexinergic neurons, 141
Hypothalamic–pituitary–adrenal axis, in metabolic disease, 127
Hypothalamus, sleep and circadian rhythms, 67
Hypothyroidism, 305
Hypotonia, 304
Hypoventilation, 203. See also Central hypoventilation syndromes
Hypoxemia, 265–266, 304
Hypoxic arousals, 115
Hypoxia, 134, 135, 139, 358, 464–465
40-Hz rhythm, 62, 68

I
Iellamo, F., 93
Imaging
normal airway, 216–218
of obstructed upper airway adenoid and tonsils, 222–223
airway length vs. cross-sectional area, 221
craniofacial structure, 223–224
fat pads, 223
phenotypes of childhood OSAS, 221
respiratory-volume-gated MRI, 222
soft palate, 223
soft tissues, 222
tongue, 223
Infants
autonomic cardiovascular regulation, during sleep effects of, 96–98
maturations, 89–91
cyclic alternating pattern, 78
OSAS, 224
Inflammation, 522–523
adenoids, 522
hsCRP, 522, 523
local airway and systemic inflammation, 522
measures in SDB, 522
and obesity hsCRP levels, 296
intermittent hypoxia, 297
leptin levels, 296–297
metabolic abnormalities, 295
Inflammatory cardiovascular biomarkers, obstructive sleep apnea, 169
Inflammatory cells, in nasal submucosa, 42
Ing, A.J., 420
Insana, S.P., 178
Inspiratory air, 49
Insulin, 124
resistance, 496
Interleukin-6, 522
International Paediatric Work Group on Arousals (IPWG), 109
Intracapsular tonsillectomy, complications, 514
Intralaminar thalamus, 62, 65
Isono, S., 14, 18, 220
8-Isopentane, 522
Israel, F., 555

J
Jacob, I.N., 345
Jacob, S.V., 191
Jankelowitz, L., 367, 368
Jaryszak, E.M., 367, 368
Jenni, O.G., 74–77
Johnson, E.O., 332
Johnson, M.C., 332
Joubert syndrome, 400, 468

K
Kaditis, A.G., 284, 286, 387, 501, 502
Kaemingk, K.L., 455
Kaleyias, J., 326, 355
Kalra, M., 283
Kawabata, I., 27
Kawashima, S., 5, 224
Kawauchi, A., 504
K complexes, EEG, 75–76
Keener, M., 74
Kennedy, D.W., 48
Khalyfa, A., 239, 482
Khan, A., 270
Kheirandish-Gozal, L., 484, 526
Kheirandish, L., 526, 527
Kiely, J.L., 352
Kiesselbach’s area, 43
Kim, J., 33, 482, 484
Kirk, V.G., 189, 190
Kirschner, R.E., 343, 344
Klein, 340
Kleitman, N., 195
Kohler, M.J., 450
L

Lamm, C., 188
Landolt, H.P., 77
Larkin, E.K., 523
Larson, M., 339
Laryngomalacia, 304, 308
Laryngopharyngeal reflux
endoscopically diagnosis, 421–422
hypopharyngeal sensor, 423
obstructive-reflux events relationship, 421–422
schematic representation, 421
symptoms, 420
Larynx
anatomic characteristics, in childhood, 9–10
normal anatomy, 9
Lateral neck x-ray
adenoidal and tonsillar enlargement, 165
upper airway evaluation, 170
Lavie, P., 50
Learning, acquired knowledge
achievement assessments, 456
breathing difficulty, 456
cyclic alternating pattern, 453
difficulties, 454
ENT clinic, 455
event-related potential (ERP), 456
morbidity, 456
NREM, 454
snoring, 455
LeBlanc, S.M., 344
Lefaivre, J.F., 345
Leiberman, A., 503
Leigh syndrome, 399–400
Leiter, J.C., 14
Lenard, Z., 91
Leptin, 61, 125, 127, 128
Leukotriene
cysteinyl, 523, 525
modifiers, 526
and receptors, 523–524
in tonsils/adenoids, 524
Leung, L.C., 479
Lewin, D.S., 447
Li, A.M., 172, 523
Limb EMG, 205
Limb-girdle muscular dystrophy (LGMD), 315–316
Lindberg, N., 432
Lingual tonsillar hypertrophy, 305
Lingual tonsillectomy, 511
Lingual tonsils, 7, 9, 27
Locus coeruleus (LC), 64
Long face syndrome, 168
Loomis, A.L., 74
Louis, J., 75
Lower esophageal sphincter (LES), 418
Lu, L.R., 283, 387
Lumeng, J.C., 246, 282, 285
Luscri, N., 307
Luteinizing hormone (LH), 61
Lymphadenoid tissues, in upper airway
growth of, 27
histology of, 26–27
immunological characteristics, in children
lymphocyte migration, in palatine tonsils, 31
palatine tonsils, immunological response in, 30–31
in OSA children, clinical aspects of, 31–33
palatine tonsils, functional morphology of
cell composition of compartments, 28
crets, 27–28
extrafollicular area, 28–29
follicular germinal center, 30
lymphoepithelium, 28, 29
lymphoid follicles, 29
Lymphoepithelium, 28, 29
Lymphoid follicles, 29
M
Macroglossia, 304
Mador, M.J., 535
Maganti, R., 355
Magnetic resonance imaging (MRI), 215, 220, 222
of upper airway, 171, 304
Mallampati scoring, 168
Mallampati, S.R., 168
Malocclusions, 544, 546
Malow, B.A., 355, 357
Mandibular advancement devices
adenotonsillectomy, 542, 545
case study, 548–549
clinical implications, 549–550
craniofacial abnormalities, 542, 543
cyclic alternating pattern (CAP), 549, 550
nasal airflow, 550
oropharyngeal exercises, 548
orthodontic treatment, 543, 545, 546, 549
OSAS, 542
pediatric SDB, common type, adult type, and
congenital type of, 542, 543
rapid maxillary expansion (RME), 544–547
research directions, 549–550
Mandibular distraction osteogenesis, 308
Mandibular retropositioning, 543, 545
Mansfield, L.E., 52
Marcus, C.L., 18, 190, 191, 308, 341, 355, 356, 479, 534
Marcus, K.L., 303
Marino, A., 5
Muscular dystrophy
Duchenne, 314
limb-girdle, 315–316
myotonic, 314–315
Muzumdar, H.V., 478
Myatt, H.M., 171
Myelodysplasia, 145–146
Myeloid-related protein 8/14 (MRP 8/14), 482
Myelomeningocele (myelodysplasia), 145–146
Myopathies, 316
Myotonic muscular dystrophy, 314–315

N
Nakra, N., 496
Nap polysomnography, 191–192
Naqvi, S., 366, 367
Narcolepsy, 67, 238
Nasal airway
airflow
direction and velocity of, 48
nasal cycle, 48
nasal valve, 47
anatomy
external nasal framework, 37–38
lateral nasal wall, 39
septum, 38
turbinates (conchae), 39
vestibule/valve, 38–39
inspiratory air
allergic inflammation, 49
warm and humidification, 49
mucosa
anterior glands, 42–43
epithelium, 41–42
intraepithelial glands, 43
seromucous glands, 43
submucosa, 42
mucus and mucociliary transport
ciliary beating, periciliary fluid, 46
dye and saccharin methods, 47
nasal secretions, sources of, 46
sol and gel phase, 46
olfaction, 49–50
neural supply, 45–46
paranasal sinuses
ethmoid, 40
frontal, 40
function of, 40–41
maxillary sinus, 40
sphenoid sinus, 40
and sleep-disordered breathing
allergic rhinitis and sleep disturbances, 51–52
in childhood, 52–53
nasal obstruction, role of, 50–51
vascular and lymphatic supplies, 45
blood supply, 44
ophthalmic and internal maxillary arteries, 43
sphenopalatine artery, 43
subepithelial and glandular zones of, 43–44

Metabolic and hormonal regulation, during sleep
circadian rhythm and metabolism, 127–128
corticotropic axis, 123
energy expenditure, 125, 126
feeding, 124–125
glucose homeostasis, 124, 126
gonadal axis, 123–124
growth hormone axis, 122
hypocretin/orexin, 126–127
hypothalamic–pituitary–adrenal axis, in metabolic
disease, 127
metabolic syndrome, 126
obesity, 125–126
prolactin secretion, 123
short sleep duration, 125–126
sleep curtailment, 122, 126, 127
thyroid axis, 123
Metabolic consequences, sleep disorders
obesity, 494
obstructive sleep apnea (OSA), 494–497
sleep disturbances, 494
Mezzacappa, E., 431
Miano, S., 78
Micrognathia, 338–340
Midfacial hypoplasia, 304, 307, 338
Miljeteig, H., 51
Miller, J.L., 398
Miller, V.A., 350
Milross, M.A., 367
Mitchell, R.B., 554
Mitchell, R.B., 304, 307, 308, 516
Mitochondrial disorders, 316
Mixter, R.C., 343
Modafinil, 65, 67
Monini, S., 550
Montelukast, 526
Montgomery-Downs, H.E., 284, 455
Morbidity, OSA, 412
Mucosa, in nasal airway, 41–43
Mucus and mucociliary transport, nasal, 46–47
Multiple sleep latency test (MSLT), 196, 208–209
Mulvaney, S.A., 433
Muscle tone and locomotion, sleep and circadian
rhythms, 65–66
Nasal intermittent positive pressure ventilation 
(N-IPPV), 272
Nasal pressure transducers, 202
Nasal prongs, 402
Nasopharyngeal airway, 220
Nasopharyngeal stenosis, 513
Nasopharyngoscopy, 171
Nasopharynx, 6, 8, 214
examination, 167
Natriuretic peptides, 502
Necdin gene, 146
Needleman, J.P., 327
Negative pressure ventilation, 402
diaphragm pacing, 557
Neonatal sleep-related breathing disorders and 
chemoreceptor function, 146
Neural supply, nasal airway, 45–46
Neurocognitive function. See Cognition, nonacquired 
knowledge
Neurological disorders, 225–226
Neuromuscular compensation, obstructive sleep 
apnea, 156
Neuromuscular disorders (NMD)
acid maltase deficiency (AMD), 315
animal models, 316
congenital muscular dystrophy, 314–315
Duchenne muscular dystrophy (DMD), 314
limb-girdle muscular dystrophy (LGMD), 315–316
management of
acid maltase myopathy, 317
congenital and metabolic myopathies, 318
Duchenne muscular dystrophy (DMD), 317
myotonic muscular dystrophy, 317
mitochondrial disorders, 316
mucus mobilization techniques, 319
noninvasive mechanical support, 319
noninvasive ventilation for diaphragmatic paresis, 
320–321
NPPV, 319–320
secretion extraction maneuvers, 318
therapeutic considerations, 318
Neuronal excitability, 358
NeuRx Diaphragm Pacing System, 558, 562
Newborns and infants, cyclic alternating pattern, 78
Ng, D.K., 283, 306, 479
Nicolás, A., 75
Nitric oxide and paranasal sinuses, 41
Nocturnal enuresis
alarm devices, 503
central hypothesis, 504
clinical implications, 504
definition of, 499
desmopressin, 503
EEG, arousal dysfunction, 504
epidemiology of, 500
etiology of, 500
pathogenetic heterogeneity
deep sleep with reduced arousability, 501–502
detrusor overactivity, 501
glomerular filtration, 502
habitual snoring, 502–503
mechanisms, 500
natriuretic peptides, 502
nocturnal polyuria, 501
SDB, 501
secondary enuresis, 499
treatment of, 503
Nocturnal hypoventilation, 368–370
Nocturnal polyuria, 501
Noehren, A., 190
Noninvasive positive pressure ventilation (NPPV), 397
Noninvasive ventilation, 377–378
Non-IQ (intelligence quotient) test, 444
Non-rapid eye movement (NREM) sleep, 92, 93, 107,
109, 443
Nørgaard, J.P., 501
Nose and sleep-disordered breathing
allergic rhinitis and sleep disturbances, 51–52
in childhood
RAST test, 52
snoring and sleep apnea, 52
steroids, 52
turbinate reductions, 52–53
nasal obstruction, role of, 50–51
Nunes, M.L., 355

O
O₂ and CO₂ chemoreceptors, 134–135, 137
Obesity, 280
Down syndrome, 304–305
with OSAS, 226
cardiovascular dysfunction, 476–478
three-dimensional reconstruction, 227
and SDB
EDS (see Excessive daytime sleepiness (EDS))
in general population sample, 292–293
inflammation, 295–297
prenatal and perinatal stress, 297–298
and short sleep duration, 125–126
and sleep, metabolic consequences, 494
Obesity hypoventilation syndrome (OHS), 246, 398
O’Brien, L.M., 283, 286, 478, 482
Obstructive apnea–hypopnea index (OAHI), 8
Obstructive hypoventilation, 155
Obstructive sleep apnea–hypopnea syndrome 
(OAHS), 246
Obstructive sleep apnea syndrome (OSA/OSAS), 4, 5,
10, 13, 15, 52, 163, 187, 198, 201, 202, 213, 
500, 522, 531, 532, 542
adenoidal and tonsillar enlargement, lateral neck  
X-ray, 165
adenotonsillectomy, 509, 515–517
airway, 153
anatomical evidence for, 214–215
and asthma
epidemiological overlap, 386–388
united airway concept, 385–386
audiotaping/videotaping, 188
brain regulatory mechanisms
cerebellar injury, 468–469
functional cerebellar impairments, 469
upper airway muscle activity and diaphragmatic
patterning, 468

cardiovascular dysfunction
adult studies, 475–476
autonomic dysfunction, 478–479
endothelial dysfunction, 482–484
impact of obesity, 476–478
systemic hypertension, 479–480
systemic inflammation and atherogenesis,
481–482
ventricular remodeling, 480–481

chemoreceptors role, 141–142
children, 153–156
clinical evaluation
daytime symptoms, 166–167
history, 164
mouth breathing, 164
neurobehavioral symptoms, 166
nighttime symptoms, 164–166
clinical implications, 227–228
clinical observations
habitual snoring, 155
obstructive hypoventilation, 155
upper airway resistance syndrome, 155
computational fluid dynamics (CFD), 219
craniofacial anomalies (see Craniofacial syndromes)
craniofacial disorders, 224–225
daytime nap, 192
determinants of obstruction
anatomy, 155–156
arousal, 156–157
neuromuscular compensation, 156
sleep state effect, 157
ventilatory control, 157
with Down syndrome (see Down syndrome)
EEG arousal, 110
and enuresis (see Nocturnal enuresis)
epidemiology
abnormal polysomnography and morbidity, 285–286
clinical implications, 288
definition, 279
 genetic predisposition and environmental
influences, 279–280
habitual snoring, 282–285
natural history, 287–288
risk factors, 285, 287
therapy, 280
feature of, 153, 155
fluid-solid interaction (FSI) models, 219
functional evidence for, 215–216
and gastroesophageal reflux (GER), 420
high risk patients, 167
history and physical assessment, 252–253
home multichannel monitoring, 191
infancy, 224
laboratory evaluation
diagnostic tests, 170

inflammatory cardiovascular biomarkers, 169
metabolic biomarkers, 169
urinary biomarkers, 170
lymphadenoid tissues, children, 31–33
metabolic disturbances
CPAP treatment, 496
interactions, 494–495
polymorphisms, 497
polysomnographic indices, 496
neurological disorders, 225–226
obesity, 226, 227
objective assessment, 254
optical coherence tomography, 219
oximetry, 189
pathophysiology and health consequences, 154
pharyngeal dilator activity, 157
physical examination, general, 167
pulmonary hypertension in SCD, 330–331
quality of life (QOL), 169
questionnaires, 253
rapid maxillary expansion, effects of, 545–547
REM and NREM sleep, 155
respiratory-gated imaging, 218
screening studies
abbreviated testing, 172–173
BEARS, 172
phase II screening, 172
phase I screening, 171–172
polysomnographic study, 173
ten-item sleep screener (TISS), 172
sleep pressure score, 113, 114
symptoms of, 164
transcriptomics, adenotonsillar hypertrophy, 239
ultrasound, 218
upper airway evaluation
computerized tomography, 171
dentoalveolar evaluation, 171
fluoroscopy, 170
lateral cephalometric radiography, 170
lateral neck x-ray, 170
magnetic resonance imaging, 171
upper airway examination
comorbid-medical disorders in, 169
dental malocclusion, 168
facial dysmorphism, 168–169
Mallampati scoring, 168
nasopharynx, 167
oropharynx, 167–168
systemic examination, 169
upper airway imaging
anatomy, 214, 215
craniofacial structures, 215
critical closing pressure of pharynx (Pcrit), 216
functional studies, 216
hypotonic technique, 216
imaging, 216–218
MRI of, 215
normal airway, 219–220
obstructed airway, 220–224
Obstructive sleep-disordered breathing, arousal, 115–116
Occipitoatlantal instability, 306
O’Donnell, A.R., 534
O’Donnell, C.P., 113
O’Driscoll, D.M., 479
Olfaction, 49–50
Olsen, K.D., 50
O’Regan, M.E., 359
Orexin/hypocretin neurons, sleep and circadian rhythms, 67
Oral cavity
anatomic characteristics, in childhood, 5
normal anatomy, 4–5
Oropharyngeal exercises, 548
Oropharynx, 6, 214
examination, 167–168
Orthodontic treatment, 543, 545, 546, 549
OSAS. See Obstructive sleep apnea syndrome (OSA/OSAS)
Overnight polysomnography (NPSG), 247, 452
Oximetry, 188–190, 204
Oxygen therapy, 376–377

P
Palatine tonsils, 7–9, 26
cell composition of compartments, 28
crypts, 27–28
extrafollicular area, 28–29
folicular germinal center, 30
immunological response in, 30–31
lymphocyte migration in, 31
lymphoepithelium, 28, 29
lymphoid follicles, 29
Paranasal sinuses, 39–41
Parasomniam, 196, 205, 206
Parasympathetic nervous system (PNS), 86
Parrino, L., 79
Parslow, P.M., 115
Patwardhan, L., 502
Pediatric obstructive sleep apnea (OSA), 163, 542
adenotonsillectomy, 515–517
and asthma
epidemiological overlap, 386–388
united airway concept, 385–386
epideleiology
abnormal polysomnography and morbidity, 285–286
clinical implications, 288
definition, 279
genetic predisposition and environmental influences, 279–280
habitual snoring, 282–285
natural history, 287–288
risk factors, 285, 287
therapy, 280
upper airway dysfunction, 281–282
health-care utilization
adenotonsillectomy, 413–414
categories, 411
cost, 411–412
medical records, 412–413
methods, 410
morbidity, 412
rate of referral, 412
Pediatric sleep-disordered breathing (SDB)
apnea–hypopnea index (AHI), 247–248, 250
arousals, 251–252
faces of common type, adult type, and congenital type, 543
golden-standard criteria
definitions of, respiratory events, 247–248
overnight polysomnography (NPSG), 247
respiratory polysomnographic values, 247, 249
non-golden-standard criteria, 252
obstructive sleep apnea syndrome
history and physical assessment, 252–253
objective assessment, 254
questionnaires, 253
spectrum
hierarchical model, 256–257
nonhierarchical model, 254, 256
principal component analysis, 254
severity clusters, 254–255
Pediatric sleep questionnaire (PSQ), 172
Pedunculopontine nucleus (PPN), 65, 66
Penaz, J., 88
Periodic breathing (PB), 207
Periodic limb movement disorder (PLMD), 180, 181, 205
Peripheral arterial tonometry (PAT)
arousal, 112, 113
autonomic function assessment, 88–89
Peripheral chemoreceptors, chronic intermittent hypoxia
autonomic abnormalities, 143, 144
carotid body sensitization, 142–144
hypertension, 142
OSA, 143
and sLTF, 142
sympathetic nerve activity (SNA), 143, 144
Peripubertal children, cyclic alternating pattern, 79
Peters, J.F., 74
Pfeiffer syndrome, 338
Pharyngeal anatomy, upper airway control, 14–16
Pharyngeal muscles role, in upper airway control, 16–18
Pharyngeal (adenoid) tonsils, 7, 8, 27
Pharyngomalacia, 304, 308
Pharynx, 214
anatomic characteristics, in childhood, 7–9
critical closing pressure of \( \text{P}_{\text{crit}} \), 216
hypopharynx, 6–7, 214
muscular layer of, 6–7
nasopharynx, 6, 214
nerve supply of, 7
normal anatomy, 5–6
oropharynx, 6, 214
Photoplethysmography (PPG), 89
PHOX2B, 145, 464–465, 560
Phrenic nerve
electrode wire and receiver, 558
integrity, 559
mechanical injury, 571
thoracoscopic view, 563, 564
Phrenic nerve conduction time (PNCT), 566
Pickwickian syndrome, 246
Pierre Robin sequence (PRS), 15
airway obstruction, 339–340
classification, 339
hypoplasia, 338
processes, 340
Pliszka, S., 431
Poets, C.S., 419
Polyalanine repeat expansion mutations (PARMs), 560
POLY-MESAM (P-M), 190, 191
Polysomnography (PSG), 177–178
vs. actigraphy, total sleep time (TST), 179, 180
epilepsy, 356
epileptiform activity, 200, 201
execution, sleep study and MSLT
airflow, 202, 203
child-friendly sleep laboratory, 198
chin EMG, 199
EEG electrode placement, International 10-20 system, 199, 200
electrocardiogram, 205
electrooculogram electrodes, placement of, 199, 201
gas exchange, 202–204
hyperventilation in, 203
limb EMG, 205
montage, recommended channels, 198, 199
pH probe, 205
positive airway pressure titration, 205
respiratory channels and scoring, 200
respiratory effort, 200, 202
respiratory event scoring, 204
sleep stages, 199–201
snoring, 204
vagal nerve stimulator channel, 205
video–audio and body position, 205
headaches, 352
intercostal EMG, 202
interpretation and reporting, 206
hypnogram, 207
normative polysomnographic values, comparison of, 208
witnessed apneas, 207
OSA, 173
audiotaping/ videotaping, 188
daytime nap, 191–192
home multichannel monitoring, 190–191
oximetry, 189
pediatric multiple sleep latency test, 208–209
periodic breathing (PB), 207
planning, sleep study and MSLT
accompanying caretaker, 197
laboratory, demystifying, 197
patient preparation, for study night, 197
sleep laboratory and interaction with clinic, 196
staffing, 196
timing, 196–197
questionnaires and logs, 206
sleep-onset REM periods (SOREMPs), 208, 209
Pontine inhibitory area, 66
Portapres™, 88
Positive airway pressure (PAP) titration, 205
Positive pressure ventilator (PPV), 402
Post-adenotonsillectomy complications, 307
weight gain, 307
Prader–Willi syndrome (PWS), 146, 466
clinical management, 397–398
respiratory control abnormalities, 397
Pre-Bötzinger complex (pre-BöTC), 138, 140
Preschool children, cyclic alternating pattern, 78
Pressure-to-flow ratios, 251
Primary nocturnal enuresis (PNE), 500–503
Primary snoring (PS), 246
Principe, J.C., 75
Pringle, M, 171
Proctor, D.F., 48
Prolactin secretion and sleep, 123
Proteomics
mass spectrometry (MS), two-dimensional gel electrophoresis, 240
shotgun approach, 240
of sleep disorders, 241
PSG. See Polysomnography (PSG)
Puberty
hormonal regulation, during sleep, 122, 124
sleep–wake pattern, 61
Pulmonary edema, 512
Pulse transit time (PTT), 89, 478
arousal, 112–113
Q
QT interval duration variability index (QTVi), 251
Quality of life (QOL), obstructive sleep apnea, 169
R
Radio-frequency (RF) signal, 566, 570
Radiographic evaluation, of upper airway, 170–171
Raine, A., 431
Rains, J., 353
Raphe nuclei (RN), 64
Rapid eye movement (REM) sleep, 60–62, 69, 92, 93, 107, 109, 192, 200, 207, 208, 443
Rapid maxillary expansion (RME), 308
  in children with OSAS, effects of
  endo-oral device, 544
  inclusion criteria, 546
  increased transverse dimensions, anterior
  displacement of, 547
  oral appliances, 545
  outcome of, 546
  methods, 544
Rapid-onset obesity with hypothalamic dysfunction,
  hypoventilation, and autonomic dysregulation
  (ROHHAD), 398–399
Recurrent infectious tonsillitis (RI), 32
Redline, S., 286, 387
Reduced functional residual capacity, 304
Regnis, J.A., 367
Reid, G.J., 431
REM sleep behavior disorder (RBD), 205
Respiratory central pattern generator (CPG), 137–138
Respiratory control
  chemoreceptors, 134
  epilepsy-related alteration
  central sleep apnea, 359–360
  sudden unexpected death in epilepsy
  (SUDEP), 360
Respiratory disturbance index (RDI), 191
Respiratory effort, polysomnography, 200, 202
Respiratory effort-related arousals (RERAs), 200,
  202, 203
Respiratory event scoring, 204
Respiratory-gated imaging, OSAS, 218, 222
Respiratory inductance plethysmography (RIP) belts,
  respiratory effort, 200, 202
Respiratory infections, 386
Respiratory pattern, 470
Reticular activating system (RAS), 63–65, 67
Retrotrapezoid nucleus (RTN), 140
Rhodes, S.K., 446
Richards, W., 455
RME. See Rapid maxillary expansion (RME)
Rockwell, A.D., 554
Ronen, O., 8
Roodman, S., 307
Rosen, D., 308
Rosen, G.M., 514
Rosenfeld, R.M., 510

S
Saeed, M.M., 192
Saito, H., 388
Sallés, C., 326
Sanchez-Armengol, A., 283, 286
Sanders, J.C., 515
Sangal, R.B., 430
Sans Capdevila, O., 502
Sarnoff, S.J., 555
Sato, K., 306
Sayk, F., 93
SCD. See Sickle cell disease (SCD)
Schechtman, V.L., 90
Scheerer, W.D., 7
Schlafke, M.E., 463
Schlau, M., 283
Schmidt, B., 272
Schmidt-Nowara, W.W., 532
School-age children, cyclic alternating pattern, 78–79
Schwab, R.J., 15
Secondary nocturnal enuresis, 503
Sensory long-term facilitation (sLTF) and carotid body
  sensitization, 142
Septum, nasal, 38
Seromucous glands, 43
Severinghaus, J.W., 554
Sevoflurane, 307
Shaul, D.B., 562
Shelton, K.E., 226
Sher, A.E., 340
Sheite, M.M., 308
Shibagaki, M., 75
Shin, C., 283
Shinomiya, S., 75
Shintani, T., 5, 224
Shires, C.B., 305
Shott, S.R., 304, 308
Sickle cell disease (SCD)
  cerebral blood flow in OSAS, 330
  evaluation, 331–332
  hemoglobinopathy, 324
  history and physical examination, 331
  morbidity and mortality, 325
  OSAS and stroke, 330
  pathophysiology, 324–325
  pulmonary hypertension and OSA, 330–331
  sleep
    ethnicity and socioeconomic status (SES), 325
    and pain crisis, 325–326
    patterns, 325
  sleep-disordered breathing (SDB)
    hypoxemia, 326–327
    nocturnal and daytime hypoxemia, 327–328
    prevalence of, 326
    pulse oximetry limitation, 328
    upper airway obstruction, 328–329
    vaso-occlusive pain crisis, 329
    stroke in, 329
  transcranial Doppler (TCD) velocities, 330
  treatment, 332–333
Sidman, J.D., 345
Sidoti, E.J., 343
SILASTIC® pouch, 563, 564
Singer, L., 343
Single nucleotide polymorphisms (SNPs), 237
Sitnick, S.L., 179
Sivan, Y., 188
Sleep and circadian rhythms, neural mechanisms
  age-related changes, in sleep-wake patterns, 61
  arousal states of, 59
  basal forebrain, 67–68
  BRAC, 60, 61
Index

brainstem  
locus coeruleus (LC), 64  
mesopontine region, nuclei in, 63  
pedunculopontine nuclei (PPN), 65, 66  
rhomb nuclei (RN), 64  
reticular activating system (RAS), 63–65  
wire diagram, 64  
desynchronized activity, 62  
development, 60–61  
electrical coupling, 64, 65, 67, 69  
electroencephalogram (EEG), 62, 63  
gamma band, 65, 66, 68  
gap junctions, 64, 65, 67  
hypothalamus, 67  
40-Hz rhythm, 62, 68  
intralaminar thalamus, 62, 65  
low-threshold spikes, 63, 68, 70  
metabolism  
cerebral blood flow, 68  
hypofrontality, 68, 69  
REM sleep, disturbance of developmental decrease in, 69  
thalamocortical dysrhythmia (TCD), 69–70  
muscle tone and locomotion, 65–66  
ponto-geniculo-occipital (PGO) waves, 62  
suprachiasmatic nucleus (SCN), 60  
thalamocortical systems, 68  
Zeitgebers, 60  
Sleep deprivation, 358  
Sleep endoscopy, 171  
Sleep fragmentation, 357  
Sleep pressure score (SPS), 250  
arousal, 113–115  
Sleep quality  
actigraphy, 367–368  
arquitectura, 366–367  
night-to-night variation, 367  
questionnaire, 366  
Sleep-related breathing disorder (SRBD), 198, 205  
Sleep spindle activity, 74–75  
Slow-wave activity (SWA), 76–77  
Slow-wave sleep (SWS), 60–62, 76, 78–81, 94–97, 122  
Smedje, H., 283  
Smith, J.R., 75  
Snoresat® monitor, 190  
Snoring, 306  
habitual, 155, 165  
polysomnography, 204  
Socioeconomic status (SES), 444  
Soft palate, 6, 9, 10, 223  
Soft tissues, 222  
Sogut, A., 284, 286, 455  
Sotka, K., 357  
Sorin, A., 514  
Spectrum, of sleep-disordered breathing  
hierarchical model, 256–257  
nonhierarchical model, 254, 256  
principal component analysis, 254  
severity clusters, 254–255  
Sphenoid sinus, 40  
Spierings, E.L., 350  
Spier, S., 367  
Spivey, J.F., 328  
Spruyt, K., 253, 254, 454  
Sterling resistor, 216  
Statham, M.M., 514  
Stebbens, V.A., 303  
Steriade, M., 74  
Sterman, M.B., 74  
St. Hilaire, 338  
Stokes, D.C., 371  
Stress, 127, 128  
Subcoeruleus nucleus, 65  
Submucosa, nasal, 42  
Sudden infant death syndrome (SIDS), 108–109  
Sulit, L.G., 387  
Sullivan, C.E., 531  
Sullivan, S., 52  
Suprachiasmatic nucleus (SCN), 60  
Suratwala, D., 374  
Swift, D.L., 48  
Sympathetic nerve activity (SNA), 143, 144  
Sympathetic nervous system (SNS), 86  
Syndromal craniofacial synostosis. See Craniofacial syndromes  
Systemic hypertension, 479–480  
T  
Tal, A., 481  
Tam, C.S., 296  
Tamisier, R., 251  
Tang, J.P.L., 247  
Tanguya, P.E., 72  
Tauman, R., 114, 250, 293, 296, 308, 516, 522, 523  
Teculescu, D.B., 283, 387  
Tektronix DPO7054 Digital Oscilloscope, 566  
Testosterone, 124  
Tezer, F.I., 359  
Thalamocortical dysrhythmia (TCD), 69–70  
Thalamocortical systems, sleep and circadian rhythms, 68  
Thermistor, 202  
Thermoregulatory loss, 465  
Thoracoscopy, view of phrenic nerve, 563, 564  
Thoresen, M., 90  
Thyroid axis and sleep, 123  
Thyrotropin (TSH), 123  
Tobacco exposure, 386  
chemoreceptors and sleep, 147  
Tobias, J.D., 307  
Tongue, 223  
anatomy, 4  
Tonsillar enlargement, lateral neck X-ray, 165  
Tonsillar hypertrophy, with OSA, 165  
Tonsillar pillar, posterior (palatopharyngeal arch), 6  
Tonsillectomy. See also Adenotonsillectomy (AT)  
intracapsular, complications, 514  
lingual, 511  
Tonsils, 7, 26–27, 222–223
Total sleep time (TST), polysomnography vs. actigraphy, 179, 180
Tourneux, P., 270
Tracheostomy, 307–308, 317, 318
decannulation, 557
Transcriptomics, 238
of sleep disorders, 238–240
Transcutaneous CO₂ (TCpCO₂), 204
Transient lower esophageal sphincter relaxation (TLESR), 418
Treather Collins syndrome, 15, 340
Trois, M.S., 304
Tsaoussoglou, M., 296
Tuberomammillary nucleus (TMN), 67
Tucson Children’s Assessment of Sleep Apnea (TuCASA), 452
Tumor necrosis factor alpha (TNF-α) induction, 481
Turbinates (conchae), 39
Twiddler’s syndrome, 560, 571

U
Uong, E.C., 304, 534
Upper airway, 13
anatomy, 214, 215
continuous positive airway pressure (CPAP), 17, 19
evaluation, 170–171
examination, 167–169
lymphadenoid tissues (see Lymphadenoid tissues, in upper airway)
obstruction, 13, 264, 340, 342, 345
OSAS
functional studies, 216
imaging, 216–218
normal, 219–220
obstructed airway, 220–224
pharyngeal anatomy, in control of critical pressure (Pcrit), 14, 16
hypertrophy of tonsils and adenoids, 15
limitations of studies, 14
obesity, 15
pediatric disorders, 15
soft tissues, 14, 15
upper airway length (UAL), 16
pharyngeal muscles, role of in children, 18
dilator muscles, 17
genioglossus (GG), 16, 17
negative-pressure reflex, 17
pathogenesis of sleep apnea, 16
sleep, 17, 18
tonic/postural muscles, 17
UAW muscle, 18
sleep disordered breathing, 18
structure development, in childhood
clinical implications, 10
larynx, 9–10
oral cavity, 4–5

V
Vagus nerve stimulation (VNS), 205, 360
Valery, P.C., 387
Vanderlaan, M., 394
Van Goozen, S., 431
Van Loosen, J., 38
Vascular supplies, nasal airway, 43–45
Vaughn, B.V., 357
Velopharyngeal insufficiency (VPI), 513
Ventilatory control instability (loop gain) and arousal effects, upper airway, 19
obstructive sleep apnea, 157
Ventilatory variability index (VVI), 251
Ventrolateral preoptic area (VLPO), 67
Videography, 205
Videotaping recordings, 188
Villa, M.P., 95, 545, 547
Vogler, R.C., 220

W
Wagener, S., 343
Waggener, T.B., 264
Waldeyer’s ring, 7, 26
Walter, L.M., 95
Wang, R.C., 501
Ward, S., 319
Ward, S.L.D., 115
Wauquier, A., 76
Weider, D.J., 503
Weintraub, Z., 269
Weissbluth, M., 454
Werner, H., 179
White, D.P., 50, 219
Wilcoxon, P., 296
Wilhoit, S.C., 51
Williams, A.J., 339
Witnessed apneas, 164, 165, 207
Wolfe, L., 400
Wulbrand, H., 108, 271

X
Xerostomia, 306
Xu, C., 219
| Y | Ye, J., 515 |
|   | Yiallourou, S., 90, 98 |
|   | Younes, M., 19 |
|   | Young, A.C., 367, 376, 377 |
|   | Young, T., 51 |

| Z | Zhang, G., 283 |
|   | Zinman, R., 373, 376, 377 |
|   | Zucconi, M., 224, 542 |
|   | Zuckerman, B., 434 |
|   | Zwillich, C.W., 50 |